Last reviewed 2026-05-18 · How we verify

antibody therapy

St. Vincent Medical Center - Los Angeles · Phase 1 active Biologic Quality 0/100

antibody therapy is a Biologic drug developed by St. Vincent Medical Center - Los Angeles. It is currently in Phase 1 development. Also known as: passive antibody therapy.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	antibody therapy
Also known as	passive antibody therapy
Sponsor	St. Vincent Medical Center - Los Angeles
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

antibody therapy CI brief — competitive landscape report
antibody therapy updates RSS · CI watch RSS
St. Vincent Medical Center - Los Angeles portfolio CI

Frequently asked questions about antibody therapy

What is antibody therapy?

antibody therapy is a Biologic drug developed by St. Vincent Medical Center - Los Angeles.

Who makes antibody therapy?

antibody therapy is developed by St. Vincent Medical Center - Los Angeles (see full St. Vincent Medical Center - Los Angeles pipeline at /company/st-vincent-medical-center-los-angeles).

Is antibody therapy also known as anything else?

antibody therapy is also known as passive antibody therapy.

What development phase is antibody therapy in?

antibody therapy is in Phase 1.

Manufacturer: St. Vincent Medical Center - Los Angeles — full pipeline
Also known as: passive antibody therapy

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing